Familial risks of ovarian cancer by age at diagnosis, proband type and histology

Guoqiao Zheng, Hongyao Yu, Anna Kanerva, Asta Försti, Kristina Sundquist, Kari Hemminki, Guoqiao Zheng, Hongyao Yu, Anna Kanerva, Asta Försti, Kristina Sundquist, Kari Hemminki

Abstract

Ovarian cancer is a heterogeneous disease. Data regarding familial risks for specific proband, age at diagnosis and histology are limited. Such data can assist genetic counseling and help elucidate etiologic differences among various histologic types of ovarian malignancies. By using the Swedish Family-Cancer Database, we calculated relative risks (RRs) for detailed family histories using a two-way comparison, which implied e.g. estimation of RRs for overall ovarian cancer when family history was histology-specific ovarian cancer, and conversely, RRs for histology-specific ovarian cancer when family history was overall ovarian cancer. In families of only mother, only sisters or both mother and sisters diagnosed with ovarian cancer, cancer risks for ovary were 2.40, 2.59 and 10.40, respectively; and were higher for cases diagnosed before the age of 50 years. All histological types showed a familial risk in two-way analyses, except mucinous and sex cord-stromal tumors. RRs for concordant histology were found for serous (2.47), endometrioid (3.59) and mucinous ovarian cancers (6.91). Concordant familial risks were highest for mucinous cancer; for others, some discordant associations, such as endometrioid-undifferentiated (9.27) and serous-undifferentiated (4.80), showed the highest RRs. Familial risks are high for early-onset patients and for those with multiple affected relatives. Sharing of different histological types of ovarian cancer is likely an indication of the complexity of the underlying mechanisms.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Age-standardized incidence in different time…
Fig 1. Age-standardized incidence in different time period for overall and eight histological types of invasive ovarian cancer.
Since the record of SNOMED was started in 1993, the periods for subtypes only included 1993–2000, 2001–2010 and 2011–2015.

References

    1. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. AACR; 2017.
    1. CentreforEpidemiology. Cancer incidence in Sweden 2012. Stockholm: The National Board of Health and Welfare, 2013.
    1. Kurman RJ, Shih I-M. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. The American journal of surgical pathology. 2010;34(3):433 10.1097/PAS.0b013e3181cf3d79
    1. Glance A. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609–16.
    1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. The Lancet. 2008;371(9609):303–14. 10.1016/S0140-6736(08)60167-1
    1. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. American journal of epidemiology. 2002;156(4):363–73.
    1. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology. 2016;34(24):2888–98. 10.1200/JCO.2016.66.8178
    1. Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakær J, et al. Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study. Cancer Epidemiology Biomarkers & Prevention. 2007;16(6):1160.
    1. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. Plos Med. 2012;9(4):e1001200 Epub 2012/05/19. 10.1371/journal.pmed.1001200 .
    1. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45–53. Epub 2009/11/17. 10.1093/aje/kwp314 .
    1. Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K. Concordant and discordant familial cancer: Familial risks, proportions and population impact. International journal of cancer. 2017;140(7):1510–6. 10.1002/ijc.30583
    1. Hemminki K, Granström C. Familial invasive and borderline ovarian tumors by proband status, age and histology. International journal of cancer. 2003;105(5):701–5. 10.1002/ijc.11151
    1. Hemminki K, Sundquist J, Brandt A. Incidence and mortality in epithelial ovarian cancer by family history of any cancer. Cancer. 2011;117(17):3972–80. 10.1002/cncr.26016
    1. Teerlink CC, Albright FS, Lins L, Cannon-Albright LA. A comprehensive survey of cancer risks in extended families. Genetics in Medicine. 2012;14(1):107–14. 10.1038/gim.2011.2
    1. Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. Journal of medical genetics. 2013:jmedgenet-2013-102015.
    1. Hemminki K, Li XJ. Familial risks of cancer as a guide to gene identification and mode of inheritance. International Journal of Cancer. 2004;110(2):291–4. 10.1002/ijc.20107
    1. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute. 2013;105(11):812–22. 10.1093/jnci/djt095
    1. Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Familial cancer. 2008;7(2):163–72. 10.1007/s10689-007-9164-6
    1. Pal T, Akbari M, Sun P, Lee J, Fulp J, Thompson Z, et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Brit J Cancer. 2012;107(10):1783 10.1038/bjc.2012.452
    1. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA oncology. 2016;2(4):482–90. 10.1001/jamaoncol.2015.5495
    1. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clinical Cancer Research. 2004;10(7):2473–81. 10.1158/1078-0432.ccr-1029-3
    1. Pal T, Permuth‐Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16. 10.1002/cncr.21536
    1. Watson P, Bützow R, Lynch HT, Mecklin J-P, Järvinen HJ, Vasen HF, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic oncology. 2001;82(2):223–8. 10.1006/gyno.2001.6279
    1. Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Advances in anatomic pathology. 2013;20(6):378–86. 10.1097/PAP.0b013e3182a92cf8
    1. Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish Family-Cancer Database 2009: Prospects for histology-specific and immigrant studies. Int J Cancer. 2010;126:2259–67. Epub 2009/07/31. 10.1002/ijc.24795 .
    1. Doll R, Cancer IUa. Cancer Incidence in Five Continents: A Technical Report: International Union Against Cancer; 1966.
    1. Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. International journal of cancer. 2008;123(8):1897–901. 10.1002/ijc.23724
    1. Kjærbye-Thygesen A, Huusom LD, Frederiksen K, Kjær SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978–2002. Comparison with other Nordic countries. Acta Obstetricia et Gynecologica Scandinavica. 2005;84(10):1006–12. 10.1111/j.0001-6349.2005.00878.x
    1. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol. 2015;138(3):741–9. Epub 2015/06/17. 10.1016/j.ygyno.2015.06.017 .
    1. Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S, et al. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. Journal of gynecologic oncology. 2016;27(1):e5 Epub 2015/10/16. 10.3802/jgo.2016.27.e5 .
    1. Ji J, Försti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta oncologica. 2008;47(6):1133–9. 10.1080/02841860701784544
    1. Conklin CM, Gilks CB, Group IMW, Sankaranarayanan, Anttila, Prat, et al. Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. Expert Review of Obstetrics & Gynecology. 2013;8(1):67–82.
    1. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. Jama. 2004;292(12):1480–9. Epub 2004/09/24. 10.1001/jama.292.12.1480 .
    1. Hemminki K, Zhang H, Czene K. Socioeconomic factors in cancer in Sweden. Int J Cancer. 2003;105:692–700. 10.1002/ijc.11150

Source: PubMed

3
订阅